This Week’s Biotech Highlights
This week in biotech was all about payers:
The UK’s National Institute for Health and Clinical Excellence (NICE), which provides guidance on use of new drugs and medical technologies, showed yet again that price is a key consideration, backing an Amgen drug only after being offered rebates by the manufacturer. This is one example of the general trend that regulatory approval is necessary, but not sufficient, for a successful product — .
Medicago, a Canadian company, because the US Department of Defense is paying $21-million towards a new 90,000 sq ft state-of-the art production facility in North Carolina. Meanwhile, . . . [more]
